Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases

Wang, Yun; Wang, Zhi Qiang; Wang, Feng Hua; Lei, Xuefen; Shu, Yan; Wang, De Shen; Zhang, Fei; Xu, Rui; Wang, Ling Yun; Li, Yu Hong

doi:10.18632/oncotarget.10145

Cited by 23 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is implied that liver functional reserve became poorer with the decrease of TC (Vere et al, 2012 ; Wang et al, 2014 ). Several studies have shown low serum TC level and low serum HDL level were associated with worse disease-free survival and overall survival in HCC patients undergoing surgical hepatectomy, breast cancer patients, colorectal cancer patients receiving adjuvant chemotherapy, and non-small-cell lung patients with EGFR mutations (Lee et al, 2016 ; Li et al, 2016 ; Wang et al, 2016 ; Zhang et al, 2017 ). However, these studies focused on the prognostic significance of single index of TC or HDL in post-surgery patients with cancers.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have reported that serum high-density lipoprotein (HDL) is in relation to incident cancers especially breast cancer. These findings imply that HDL might play a major role in tumorigenesis and tumor progression (Lim et al, 2007 ; Li et al, 2016 ; Wang et al, 2016 ). However, an integrated indicator based on serum TC and HDL levels, which might be superior to reflect the correlation between hepatic damage and tumor stages, has not yet been reported in HCC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection

et al. 2017

View full text Add to dashboard Cite

Purpose: We have developed a systemic hepatic-damage index (SHI) based on serum total cholesterol (TC) and high density lipoprotein levels (HDL) and determined its prognostic significance in hepatocellular carcinoma (HCC) patients undergoing resection.Experimental Design: The SHI was analyzed in the training cohort of 188 HCC patients and in the validation cohort of 177 HCC patients. The systemic immune-inflammation index (SII) scores in the validation cohorts were also measured. Area under the receiver operating characteristic curve (AUC) was used to explore the prediction accuracy in HCC patients.Results: An optimal cutoff point for the SHI of 2.84 stratified the HCC patients into high SHI (>2.84) and low SHI (≤2.84) groups in the training cohort. Univariate and multivariate analyses revealed the SHI was an independent predictor for overall survival and relapse-free survival, and prognostic for patients with negative α-fetoprotein and Barcelona Clinic Liver Cancer stage 0+A. The AUCs of the SHI for survival and recurrence were higher than other conventional clinical indices. Low SHI significantly correlated with vascular invasion. The SII scores were significantly higher in patients with low SHI compared with those with high SHI. HCC patients in SHI ≤ 2.84 group had shorter recurrence time and lower survival rate than HCC patients in SHI > 2.84 group.Conclusions: The SHI was a potential biomarker for assessing HCC prognosis, and improving SHI level in HCC patients may be a promising therapeutic strategy decision. The poor outcome in HCC patients with low SHI scores might increase SII scores, increasing the possibility of recurrence and metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Interestingly, post-treatment ApoA-I levels also seem to confer prognostic significance. A retrospective study of colorectal cancer patients treated with surgery and adjuvant chemotherapy showed that relatively increased levels of HDL-c and ApoA-I, one month after the completion of chemotherapy, were associated with better prognosis [144]. ApoA-I levels have been especially evaluated in response to chemosensitivity.…”

Section: A Potential Protective Role Of Apoa-i Against Cancer: Evimentioning

confidence: 99%

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer

Georgila

Vyrla

Δράκος

2019

Cancers

136

118

View full text Add to dashboard Cite

Apolipoprotein A-I (ApoA-I), the major protein component of high-density lipoproteins (HDL) is a multifunctional protein, involved in cholesterol traffic and inflammatory and immune response regulation. Many studies revealing alterations of ApoA-I during the development and progression of various types of cancer suggest that serum ApoA-I levels may represent a useful biomarker contributing to better estimation of cancer risk, early cancer diagnosis, follow up, and prognosis stratification of cancer patients. In addition, recent in vitro and animal studies disclose a more direct, tumor suppressive role of ApoA-I in cancer pathogenesis, which involves anti-inflammatory and immune-modulatory mechanisms. Herein, we review recent epidemiologic, clinicopathologic, and mechanistic studies investigating the role of ApoA-I in cancer biology, which suggest that enhancing the tumor suppressive activity of ApoA-I may contribute to better cancer prevention and treatment.

show abstract

“…The level of some lipoproteins also seems to be of prognostic significance. In case of CRC, for example, elevated high-density lipoprotein cholesterol (HDL-C) levels during chemotherapy showed a positive effect on overall survival (OS) and diseasefree survival (DFS) [285], whereas the higher level of LDL-C found in patients with metastatic CRC (mCRC), as well as the LDL-C to HDL-C ratio (LHR), acted as independent indicators associated with a worse prognosis [286].…”

Section: Tumor-induced Metabolic Changes Interfere With the Profile Omentioning

confidence: 99%

Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance

2020

View full text Add to dashboard Cite

Background Tumor initiation and subsequent progression are usually long-term processes, spread over time and conditioned by diverse aspects. Many cancers develop on the basis of chronic inflammation; however, despite dozens of years of research, little is known about the factors triggering neoplastic transformation under these conditions. Molecular characterization of both pathogenetic states, i.e., similarities and differences between chronic inflammation and cancer, is also poorly defined. The secretory activity of tumor cells may change the immunophenotype of immune cells and modify the extracellular microenvironment, which allows the bypass of host defense mechanisms and seems to have diagnostic and prognostic value. The phenomenon of immunosuppression is also present during chronic inflammation, and the development of cancer, due to its duration, predisposes patients to the promotion of chronic inflammation. The aim of our work was to discuss the above issues based on the latest scientific insights. A theoretical mechanism of cancer immunosuppression is also proposed. Conclusions Development of solid tumors may occur both during acute and chronic phases of inflammation. Differences in the regulation of immune responses between precancerous states and the cancers resulting from them emphasize the importance of immunosuppressive factors in oncogenesis. Cancer cells may, through their secretory activity and extracellular transport mechanisms, enhance deterioration of the immune system which, in turn, may have prognostic implications.

show abstract

Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases

Abstract: Background: The phenomenon of chemotherapy-related lipid alterations has been reported based on a small number of patients and varies among different cancers. However, little is known about these alterations in colorectal cancer (CRC) patients.

Cited by 23 publications

References 26 publications

Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection

Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer

Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance

Contact Info

Product

Resources

About